Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025 Program will feature presentations from ovarian...
October 23, 2025 10:01 ET | Source: Imunon, Inc.

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in...
October 14, 2025 08:20 ET | Source: Imunon, Inc.

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on...
September 02, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a...
August 28, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the...
August 05, 2025 16:00 ET | Source: Imunon, Inc.

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq:...
July 28, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Announces Stock Dividend Boosting Shareholder Value

Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc....
July 23, 2025 08:00 ET | Source: Imunon, Inc.

IMUNON Announces Reverse Stock Split

LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock...
July 15, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
June 30, 2025 08:00 ET | Source: Imunon, Inc.

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period

LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in...